High Katherine A

High Katherine A is listed in filings as Director at CRISPR Therapeutics AG. This profile follows SEC Form 4 activity through Jun 9, 2026, including 4 public disclosures. Recent filings connect the profile to CRISPR Therapeutics AG (CRSP) and Incyte Corp (INCY). The current snapshot covers public activity from Jun 6, 2025 to Jun 9, 2026. Reported amounts are shown as $673.9K to $501.4K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.